Teva Pharmaceutical Industries today announced that it will immediately launch to Diltiazem Extended Release Capsules (once-a-day) in all dosage strengths.
Diltiazem ER is the generic equivalent of Hoechst's Cardizem CD, which is indicated for the treatment of hypertension and angina. Sales for Cardizem CD in United States for the twelve months ended June 30th, 1999 exceeded $650 million.
Earlier Biovail Corporation International (NYSE: TSE: BVF) received final approval from the FDA for the generic version Cardizem CD. Teva has exclusive marketing rights from Biovail for the United States.
Teva Pharmaceutical Industries Limited is Israel's largest pharmaceutical company, with 80% of its sales outside Israel, mainly in the United States. The Company develops, manufactures, and markets generic and branded human pharmaceuticals, active pharmaceutical ingredients, medical disposables and veterinary products.
Published by Israel's Business Arena on December 27, 1999.